title: Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension.
abstract: BACKGROUND
  The presence of dysfunctional von Willebrand factor (vWF) in pulmonary arterial hypertension (PAH) was suggested to be related to increased proteolysis.
  
  
  RESULTS
  In 10 patients with severe PAH, we studied the proteolysis of plasma vWF (vWF levels, multimeric distribution, proteolytic pattern, and cleaving protease activity) and hemodynamic variables (mean pulmonary artery pressure, cardiac index, and total pulmonary vascular resistance) at baseline and 30 days after initiation of continuous prostacyclin infusion. At baseline, vWF levels were significantly increased, vWF proteolysis was excessive, and vWF-cleaving protease activity remained normal. These biological abnormalities were reversible and paralleled the improvement of hemodynamics under vasodilator treatment with prostacyclin.
  
  
  CONCLUSIONS
  The excessive proteolysis of vWF in PAH is likely to be related to an increased susceptibility of vWF to proteases induced by high shear rates rather than to an enhanced release of enzymes.
authors.affiliation: Service d'Hématologie Biologique, Hôpital Antoine-Béclère, Clamart, France.
authors.forename: A
authors.initials: A
authors.lastname: Veyradier
authors.forename: T
authors.initials: T
authors.lastname: Nishikubo
authors.forename: M
authors.initials: M
authors.lastname: Humbert
authors.forename: M
authors.initials: M
authors.lastname: Wolf
authors.forename: O
authors.initials: O
authors.lastname: Sitbon
authors.forename: G
authors.initials: G
authors.lastname: Simonneau
authors.forename: J P
authors.initials: JP
authors.lastname: Girma
authors.forename: D
authors.initials: D
authors.lastname: Meyer
mesh_terms: D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001794:Blood Pressure / Q000187:drug effects; D004334:Drug Administration Schedule; D011464:Epoprostenol / Q000008:administration & dosage*; D005260:Female; D006334:Heart Function Tests / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology*; D007262:Infusions, Intravenous; D008297:Male; D008666:Metalloendopeptidases / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D011651:Pulmonary Artery / Q000503:physiopathology; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects; D014841:von Willebrand Factor / Q000378:metabolism*
chemical_list: D000959:Antihypertensive Agents; D010446:Peptide Fragments; D014841:von Willebrand Factor; D011464:Epoprostenol; D051722:ADAM Proteins; D008666:Metalloendopeptidases; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human